Otros idiomas Nykode Therapeutics

Acciones

VACC

NO0010714785

Mercado cerrado - Oslo Bors Otros sitios de cotización 16:45:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
15,29 ^NOK	+4,23 %		+5,52 %	-28,55 %

20/06	Nykode Therapeutics anuncia avances en su plataforma de vacunas inversas en la reunión FOCIS 2024	CI
11/06	Nykode Therapeutics ASA anuncia que la vacuna contra el cáncer ARNm-LNP demuestra una eficacia superior	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Nykode Therapeutics : Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20/06
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20/06
Nykode Therapeutics : presentation from ABGSC Seminar on Autoimmunity, Transplantation & Inflammation	11/06
Nykode Therapeutics ASA Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy	11/06
Nykode Therapeutics : Q1 2024 Financial Results – presentation	14/05
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Nykode Therapeutics : Q1 2024 Financial Results	14/05
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14/05
Nykode Therapeutics : reports Q1 2024 Financial Results	14/05
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	19/04
Nykode Therapeutics : Remuneration Report 2023	19/04
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19/04
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21/03
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19/03
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14/12
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	27/10/23
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding	25/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nykode Therapeutics

Acciones

VACC

NO0010714785

Otros idiomas

Filtros